Advances in immuno-oncology biomarkers for gastroesophageal cancer: Programmed death ligand 1, microsatellite instability, and beyond
- PMID: 29991874
- PMCID: PMC6034145
- DOI: 10.3748/wjg.v24.i25.2686
Advances in immuno-oncology biomarkers for gastroesophageal cancer: Programmed death ligand 1, microsatellite instability, and beyond
Abstract
Blockade of the programmed death ligand 1 (PD-L1) and programmed cell death 1 (PD-1) receptor axis represents an effective form of cancer immunotherapy. Preclinical evidence initially suggested that gastric and gastroesophageal junction (GEJ) cancers are potentially immunotherapy-sensitive tumors. Early phase clinical trials have demonstrated promising antitumor activity with PD-1/PD-L1 blockade in advanced or metastatic gastric/GEJ cancer. Microsatellite instability (MSI) and PD-L1 expression have been shown to predict higher response to PD-1 inhibitors as highlighted by the recent approvals of pembrolizumab in treatment-refractory solid tumors with MSI status and the third-line or greater treatment of PD-L1 positive advanced gastric/GEJ cancers. However, predictive and prognostic biomarkers remain an ongoing need. In this review, we detail the preclinical evidence and early tissue biomarker analyses illustrating potential predictive biomarkers to PD-1/PD-L1 blockade in gastric/GEJ cancer. We also review the clinical development of PD-1/PD-L1 inhibitors in gastric/GEJ cancer and highlight several areas in need of future investigation in order to optimize the efficacy of PD-1/PD-L1 blockade in gastric/GEJ cancer.
Keywords: Gastric cancer; Immunotherapy; Microsatellite instablility; Programmed cell death 1; Programmed death ligand 1.
Conflict of interest statement
Conflict-of-interest statement: Chao J has received research support (institutional), consulting, and speaker fees from Merck; Klempner SJ has received research support from Leap Therapeutics and Astellas (institutional), and consulting fees from Boston Biomedical and Lilly Oncology. The remaining authors declare no conflicts of interest.
Similar articles
-
Beyond the PD-L1 horizon: In search for a good biomarker to predict success of immunotherapy in gastric and esophageal adenocarcinoma.Cancer Lett. 2019 Feb 1;442:279-286. doi: 10.1016/j.canlet.2018.11.001. Epub 2018 Nov 9. Cancer Lett. 2019. PMID: 30419350
-
FDA Approval Summary: Pembrolizumab for Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing PD-L1.Oncologist. 2019 Jan;24(1):103-109. doi: 10.1634/theoncologist.2018-0221. Epub 2018 Aug 17. Oncologist. 2019. PMID: 30120163 Free PMC article.
-
Immuno-Oncology Biomarkers for Gastric and Gastroesophageal Junction Adenocarcinoma: Why PD-L1 Testing May Not Be Enough.Oncologist. 2018 Oct;23(10):1171-1177. doi: 10.1634/theoncologist.2018-0034. Epub 2018 Apr 27. Oncologist. 2018. PMID: 29703766 Free PMC article.
-
Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part II-The Challenge of Programmed Death Ligand-1 Testing and Its Role in Microsatellite Instability-High Colorectal Cancer.Arch Pathol Lab Med. 2018 Jan;142(1):26-34. doi: 10.5858/arpa.2017-0041-RA. Epub 2017 Nov 9. Arch Pathol Lab Med. 2018. PMID: 29120224 Review.
-
Pembrolizumab for treatment of advanced gastric and gastroesophageal junction adenocarcinoma.Future Oncol. 2018 Feb;14(5):417-430. doi: 10.2217/fon-2017-0436. Epub 2017 Nov 2. Future Oncol. 2018. PMID: 29094609 Free PMC article. Review.
Cited by
-
The Prognostic Value of the Prognostic Nutritional Index in Patients with Advanced or Metastatic Gastric Cancer Treated with Immunotherapy.Nutrients. 2023 Oct 8;15(19):4290. doi: 10.3390/nu15194290. Nutrients. 2023. PMID: 37836573 Free PMC article.
-
Identification and validation of a novel prognostic model for gastric cancer based on m7G-related genes.Transl Cancer Res. 2023 Jul 31;12(7):1836-1851. doi: 10.21037/tcr-22-2614. Epub 2023 Jul 28. Transl Cancer Res. 2023. PMID: 37588749 Free PMC article.
-
The efficacy and safety of first‑line anti‑PD‑1/PD‑L1 immunotherapy for gastric esophageal cancer: A systematic review and meta‑analysis of phase III randomized controlled trials.Exp Ther Med. 2023 Mar 28;25(5):216. doi: 10.3892/etm.2023.11915. eCollection 2023 May. Exp Ther Med. 2023. PMID: 37123204 Free PMC article.
-
Prevalence of Epstein-Barr Virus Infection and Mismatch Repair Protein Deficiency and the Correlation of Immune Markers in Tibetan Patients with Gastric Cancer.Biomed Res Int. 2022 Jun 13;2022:2684065. doi: 10.1155/2022/2684065. eCollection 2022. Biomed Res Int. 2022. PMID: 35734348 Free PMC article.
-
Construction of ovarian metastasis-related immune signature predicting prognosis of gastric cancer patients.Cancer Med. 2023 Jan;12(1):913-929. doi: 10.1002/cam4.4857. Epub 2022 May 27. Cancer Med. 2023. PMID: 35621244 Free PMC article.
References
-
- Dong H, Zhu G, Tamada K, Chen L. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med. 1999;5:1365–1369. - PubMed
-
- Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited. Annu Rev Immunol. 2005;23:515–548. - PubMed
-
- Nishimura H, Nose M, Hiai H, Minato N, Honjo T. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity. 1999;11:141–151. - PubMed
-
- Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8:793–800. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials